COH Stock Overview

Provides implantable hearing solutions for children and adults worldwide. More details

COH fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	4/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings are forecast to grow 11.97% per year

Earnings have grown 31.5% per year over the past 5 years

Risk Analysis

COH passed our risk checks.

Cochlear Limited Competitors

Sonic Healthcare

ASX:SHL

AU$12.5b

Austco Healthcare

ASX:AHC

AU$105.6m

Ansell

ASX:ANN

AU$5.0b

Sigma Healthcare

ASX:SIG

AU$33.1b

Price History & Performance

Summary of share price highs, lows and changes for Cochlear
Historical stock prices
Current Share Price	AU$267.96
52 Week High	AU$350.31
52 Week Low	AU$255.69
Beta	0.43
1 Month Change	3.15%
3 Month Change	-8.74%
1 Year Change	-18.78%
3 Year Change	19.01%
5 Year Change	46.50%
Change since IPO	8,983.39%

Cochlear (ASX:COH) Will Pay A Larger Dividend Than Last Year At A$2.15

Mar 06

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

Feb 23

New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects

Feb 23 Focus on adult and senior markets in developed countries could drive revenue and net margin growth through increased sales volume.

Recent updates

Cochlear (ASX:COH) Will Pay A Larger Dividend Than Last Year At A$2.15

Mar 06

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

Feb 23

New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects

Feb 23 Focus on adult and senior markets in developed countries could drive revenue and net margin growth through increased sales volume.

Is Cochlear Limited (ASX:COH) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 04

We Think Shareholders May Consider Being More Generous With Cochlear Limited's (ASX:COH) CEO Compensation Package

Oct 18

Cochlear Limited's (ASX:COH) Shareholders Might Be Looking For Exit

Sep 19

Cochlear Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Aug 16

Investors Could Be Concerned With Cochlear's (ASX:COH) Returns On Capital

Aug 01

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

Jun 08

Shareholder Returns

	COH	AU Medical Equipment	AU Market
7D	-0.4%	-1.2%	-0.4%
1Y	-18.8%	-13.0%	-1.7%

Return vs Industry: COH underperformed the Australian Medical Equipment industry which returned -13% over the past year.

Return vs Market: COH underperformed the Australian Market which returned -1.7% over the past year.

Price Volatility

Is COH's price volatile compared to industry and market?
COH volatility
COH Average Weekly Movement	5.0%
Medical Equipment Industry Average Movement	10.9%
Market Average Movement	8.4%
10% most volatile stocks in AU Market	16.0%
10% least volatile stocks in AU Market	3.5%

Stable Share Price: COH has not had significant price volatility in the past 3 months compared to the Australian market.

Volatility Over Time: COH's weekly volatility (5%) has been stable over the past year.

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Cochlear

Analyst Price Target

Consensus Narrative from 16 Analysts

New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects

Key Takeaways Focus on adult and senior markets in developed countries could drive revenue and net margin growth through increased sales volume. New product launches and geographic expansion, especially in Europe and emerging markets, support competitive positioning and incremental revenue growth.

View narrative

AU$287.60

6.8% undervalued

9.95%

Revenue growth p.a.

Updated

View Cochlear Community

About the Company

Founded	Employees	CEO	Website
1981	5,047	Dig Howitt	www.cochlear.com

Cochlear Limited provides implantable hearing solutions for children and adults worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. The company was founded in 1981 and is headquartered in Sydney, Australia.

Cochlear Limited Fundamentals Summary

How do Cochlear's earnings and revenue compare to its market cap?
COH fundamental statistics
Market cap	AU$17.52b
Earnings (TTM)	AU$370.50m
Revenue (TTM)	AU$2.31b

47.3x

P/E Ratio

7.6x

P/S Ratio

Is COH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
COH income statement (TTM)
Revenue	AU$2.31b
Cost of Revenue	AU$573.80m
Gross Profit	AU$1.74b
Other Expenses	AU$1.36b
Earnings	AU$370.50m

Last Reported Earnings

Dec 30, 2024

Next Earnings Date

Aug 15, 2025

Earnings per share (EPS)	5.67
Gross Margin	75.15%
Net Profit Margin	16.05%
Debt/Equity Ratio	0%

How did COH perform over the long term?

See historical performance and comparison

Dividends

1.6%

Current Dividend Yield

75%

Payout Ratio

Does COH pay a reliable dividends?

See COH dividend history and benchmarks

When do you need to buy COH by to receive an upcoming dividend?
Cochlear dividend dates
Ex Dividend Date	Mar 20 2025
Dividend Pay Date	Apr 14 2025
Days until Ex dividend	14 days
Days until Dividend pay date	11 days

Does COH pay a reliable dividends?

See COH dividend history and benchmarks

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/04/02 20:20
End of Day Share Price	2025/04/02 00:00
Earnings	2024/12/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cochlear Limited is covered by 29 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Hester	ANZ Equities Pty Limited
Saul Hadassin	Barrenjoey Markets Pty Limited
Stuart Roberts	Bell Potter

COH Stock Overview

Rewards

Risk Analysis

Cochlear Limited Competitors

ASX:SHL

AU$12.5b

ASX:AHC

AU$105.6m

ASX:ANN

AU$5.0b

ASX:SIG

AU$33.1b

Price History & Performance

Recent News & Updates

Upcoming dividend of AU$2.15 per share

Cochlear (ASX:COH) Will Pay A Larger Dividend Than Last Year At A$2.15

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects

First half dividend of AU$2.15 announced

First half 2025 earnings: EPS in line with expectations, revenues disappoint

Recent updates

Upcoming dividend of AU$2.15 per share

Cochlear (ASX:COH) Will Pay A Larger Dividend Than Last Year At A$2.15

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

New Cochlear Implant Launch And Market Expansion Will Strengthen Future Prospects

First half dividend of AU$2.15 announced

First half 2025 earnings: EPS in line with expectations, revenues disappoint

Cochlear Limited Announces Ordinary Dividend for the Period of Six Months Ended December 31, 2024, Payable on April 14, 2025

Investor sentiment deteriorates as stock falls 15%

Now 21% overvalued after recent price rise

Is Cochlear Limited (ASX:COH) Worth AU$310 Based On Its Intrinsic Value?

Earnings Not Telling The Story For Cochlear Limited (ASX:COH)

Some Investors May Be Worried About Cochlear's (ASX:COH) Returns On Capital

CEO, MD exercised options and sold AU$3.1m worth of stock

Is Cochlear Limited (ASX:COH) Expensive For A Reason? A Look At Its Intrinsic Value

We Think Shareholders May Consider Being More Generous With Cochlear Limited's (ASX:COH) CEO Compensation Package

Now 20% overvalued

Cochlear Limited's (ASX:COH) Shareholders Might Be Looking For Exit

CEO, MD exercised options and sold AU$613k worth of stock

Stu Sayers to Appoint as President, Asia Pacific & Latin America of Cochlear Limited, Effective from 1 January 2025

Upcoming dividend of AU$2.10 per share

Final dividend of AU$2.10 announced

Cochlear Limited Announces Ordinary Dividend for the Period of Six Months Ended June 30, 2024, Payable on October 10, 2024

Cochlear Limited Just Missed EPS By 7.4%: Here's What Analysts Think Will Happen Next

Full year 2024 earnings: EPS misses analyst expectations

Cochlear Limited (ASX:COH) announces an Equity Buyback for AUD 75 million worth of its shares.

Investors Could Be Concerned With Cochlear's (ASX:COH) Returns On Capital

Cochlear Limited Appoints Caroline Clarke as Non-Executive Director, Effective from 2 September 2024

Cochlear Limited Announces Executive Changes

Here's Why We Think Cochlear (ASX:COH) Is Well Worth Watching

Cochlear Limited (ASX:COH) acquired Oticon Medical A/s from Demant A/S (CPSE:DEMANT).

Cochlear Limited Announces Company Secretary Changes

Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-Old

Upcoming dividend of AU$2.00 per share

First half dividend increased to AU$2.00

First half 2024 earnings: EPS in line with expectations, revenues disappoint

Price target increased by 7.0% to AU$272

Upcoming dividend of AU$1.75 per share at 1.2% yield

Cochlear Limited Introduces Next Generation Cochlear Osia System with Ability to Have MRI at 3.0 T

Cochlear Limited to Report Fiscal Year 2024 Results on Aug 15, 2024

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Cochlear Limited Announces Andrew Denver, Non-Executive Director Intention to Retire At AGM to Be Held on 17 October 2023

Upcoming dividend of AU$1.55 per share at 1.3% yield

Cochlear Limited Provides Earnings Outlook for the Year 2023

Cochlear Limited (ASX:COH) announces an Equity Buyback for AUD 75 million worth of its shares.

Cochlear Limited, Annual General Meeting, Oct 17, 2023

FDA Approves Cochlear Limited's Nucleus 8 Sound Processor, Smaller, Smarter, Better Connected Cochlear Implant Technology

Key Executive recently bought AU$97k worth of stock

Upcoming dividend of AU$1.45 per share

Full year 2022 earnings: EPS misses analyst expectations

Cochlear Announces Final Dividend Payable on 17 October 2022

Cochlear Limited Appoints Karen Penrose to Board, Effective on 1 July 2022

Cochlear Limited, Annual General Meeting, Oct 18, 2022

Cochlear Limited to Report First Half, 2023 Results on Feb 15, 2023

Upcoming dividend of AU$1.55 per share

Investor sentiment improved over the past week

First half 2022 earnings: EPS and revenues exceed analyst expectations

Cochlear Limited Announces Interim Dividend Expected to Be Payable on 21 April 2022

FDA Approves Cochlear Nucleus Implants for Unilateral Hearing Loss/Single-Sided Deafness

Independent Non-Executive Director recently bought AU$56k worth of stock